Cephalon Investor Sues Over $5.7B Valeant Bid Rebuff
A Cephalon Inc. shareholder lodged a proposed class action Thursday in Delaware seeking to force the drugmaker's board to engage Valeant Pharmaceuticals International Inc. in its $5.7 billion buyout offer....To view the full article, register now.
Already a subscriber? Click here to view full article